1. Blood Cancer J. 2023 Feb 13;13(1):25. doi: 10.1038/s41408-023-00796-9.

Circulating tumour DNA analysis predicts relapse and improves risk 
stratification in primary refractory multiple myeloma.

Mithraprabhu S(1)(2), Reynolds J(3)(4), Turner R(4), Quach H(5), Horvath N(6), 
Kerridge I(7), Kalff A(4), Bergin K(3)(4), Hocking J(4), Yuen F(4), Khong 
T(3)(4), Durie BM(8), Spencer A(9)(10).

Author information:
(1)Australian Centre for Blood Diseases, Alfred Health-Monash University, 
Melbourne, VIC, Australia. Durga.mithraprabhu@monash.edu.
(2)Department of Malignant Haematology and Stem Cell Transplantation, Alfred 
Hospital, Melbourne, VIC, Australia. Durga.mithraprabhu@monash.edu.
(3)Australian Centre for Blood Diseases, Alfred Health-Monash University, 
Melbourne, VIC, Australia.
(4)Department of Malignant Haematology and Stem Cell Transplantation, Alfred 
Hospital, Melbourne, VIC, Australia.
(5)St.Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.
(6)Royal Adelaide Hospital, Adelaide, SA, Australia.
(7)Royal North Shore Hospital, Sydney, NSW, Australia.
(8)Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, USA.
(9)Australian Centre for Blood Diseases, Alfred Health-Monash University, 
Melbourne, VIC, Australia. Andrew.spencer@monash.edu.
(10)Department of Malignant Haematology and Stem Cell Transplantation, Alfred 
Hospital, Melbourne, VIC, Australia. Andrew.spencer@monash.edu.

DOI: 10.1038/s41408-023-00796-9
PMCID: PMC9925790
PMID: 36781844 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing interests.